J G Jurcic

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
  2. doi request reprint What happened to anti-CD33 therapy for acute myeloid leukemia?
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Hematol Malig Rep 7:65-73. 2012
  3. ncbi request reprint Ab therapy of AML: native anti-CD33 Ab and drug conjugates
    J G Jurcic
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, New York, USA
    Cytotherapy 10:7-12. 2008
  4. ncbi request reprint Diagnosis and treatment of acute promyelocytic leukemia
    Joseph G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:337-44. 2007
  5. ncbi request reprint Monitoring PML-RARalpha in acute promyelocytic leukemia
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:391-8. 2003
  6. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
  7. ncbi request reprint Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
    J G Jurcic
    Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 98:2651-6. 2001
  8. ncbi request reprint Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Hematol 7:247-54. 2000
  9. ncbi request reprint Antibody therapy of acute myelogenous leukemia
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Biother Radiopharm 15:319-26. 2000
  10. ncbi request reprint Antibody immunotherapy for leukemia
    J G Jurcic
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:114-22. 2000

Detail Information

Publications26

  1. ncbi request reprint Immunotherapy for acute myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 458, New York, NY 10021, USA
    Curr Oncol Rep 7:339-46. 2005
    ..T-cell recognition of peptide antigens presented on the cell surface in combination with major histocompatibility complex antigen provides another potentially promising approach for the treatment of AML...
  2. doi request reprint What happened to anti-CD33 therapy for acute myeloid leukemia?
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Curr Hematol Malig Rep 7:65-73. 2012
    ....
  3. ncbi request reprint Ab therapy of AML: native anti-CD33 Ab and drug conjugates
    J G Jurcic
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, New York, USA
    Cytotherapy 10:7-12. 2008
    ....
  4. ncbi request reprint Diagnosis and treatment of acute promyelocytic leukemia
    Joseph G Jurcic
    Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 9:337-44. 2007
    ..The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups...
  5. ncbi request reprint Monitoring PML-RARalpha in acute promyelocytic leukemia
    Joseph G Jurcic
    Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 5:391-8. 2003
    ..APL provides a useful model in which therapy is targeted to an underlying genetic aberration and treatment is adapted based on monitoring of residual disease...
  6. ncbi request reprint Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  7. ncbi request reprint Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia
    J G Jurcic
    Leukemia, Hematology, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 98:2651-6. 2001
    ..Conversely, a confirmed positive test is highly predictive of relapse...
  8. ncbi request reprint Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Curr Opin Hematol 7:247-54. 2000
    ..Clinical trials exploiting the new understanding of the T cell immunology are underway...
  9. ncbi request reprint Antibody therapy of acute myelogenous leukemia
    J G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Biother Radiopharm 15:319-26. 2000
    ..Additionally, directed chemotherapy using an anti-CD33-calicheamicin conjugate (CMA-676) has produced remissions in patients with relapsed AML...
  10. ncbi request reprint Antibody immunotherapy for leukemia
    J G Jurcic
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Oncol Rep 2:114-22. 2000
    ..Targeted alpha particle therapy offers the possibility of selective tumor cell kill while sparing surrounding normal cells. Antibody-drug conjugates and immunotoxins have produced complete remissions in leukemia...
  11. ncbi request reprint Antibody therapy for residual disease in acute myelogenous leukemia
    J G Jurcic
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 38:37-45. 2001
    ..Antibody-drug conjugates, such as gemtuzumab ozogamicin, composed of a humanized anti-CD33 mAb and calicheamicin, have produced complete remissions in patients with relapsed AML and are likely to be active in the postremission setting...
  12. ncbi request reprint Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia
    K S Kolbert
    Department of Medical Physics Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 42:27-32. 2001
    ..CONCLUSION: Rate images make it possible to succinctly display kinetic information about an agent's behavior over the entire acquired image...
  13. ncbi request reprint Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias
    J M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY, USA
    Bone Marrow Transplant 32:549-56. 2003
    ..These studies show the feasibility of adding CD33-targeted radioimmunotherapy to a standard BMT preparative regimen; however, randomized trials will be needed to prove a benefit to intensified conditioning with radioimmunotherapy...
  14. pmc Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses
    Nicole Lamanna
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:491-7. 2009
    ..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
  15. ncbi request reprint Monoclonal antibody therapy of APL
    P G Maslak
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Curr Top Microbiol Immunol 313:205-19. 2007
    ..The preliminary results have been promising, and further development of this modality as an effective adjunct to existing treatment regimens will most certainly occur in the near future...
  16. doi request reprint Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
    Azra Raza
    St Vincent s Comprehensive Cancer Center, New York, NY, USA
    Leuk Lymphoma 50:1336-44. 2009
    ..In contrast to aggressive conventional chemotherapy, lintuzumab was administered in an ambulatory clinic setting with acceptable toxicity...
  17. ncbi request reprint The promise of targeted {alpha}-particle therapy
    Deborah A Mulford
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Nucl Med 46:199S-204S. 2005
    ..Treatment of patients with less-advanced disease and, ultimately, randomized trials comparing targeted alpha-particle therapy with standard approaches will be required to determine the clinical utility of this approach...
  18. ncbi request reprint Radioimmunotherapy for acute leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Control 9:106-13. 2002
    ..In this article, we summarize the role of radioimmunotherapy in the treatment of leukemia...
  19. ncbi request reprint Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 21:1278-84. 2003
    ..Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs...
  20. ncbi request reprint Acute myeloid leukemia with t(5;18)(q35;q21)
    E S Wang
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Cancer Genet Cytogenet 127:71-3. 2001
    ..Possible molecular mechanisms underlying the pathogenesis of the disease are discussed...
  21. ncbi request reprint Antibody-based treatment of acute myeloid leukaemia
    Deborah A Mulford
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 458, New York, NY 10021, USA
    Expert Opin Biol Ther 4:95-105. 2004
    ....
  22. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Nicole Lamanna
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1575-81. 2006
    ..We previously reported that pentostatin and cyclophosphamide (PC) is active and well-tolerated in patients with relapsed or refractory CLL. Subsequently, we added rituximab, and now report on this three-drug combination...
  23. ncbi request reprint Radioimmunotherapy of leukemia
    John M Burke
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NewYork 10021, USA
    Adv Pharmacol 51:185-208. 2004
  24. ncbi request reprint Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin
    Timothy B Aliff
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 97:1025-32. 2003
    ..The authors treated a group of patients with amphotericin-refractory IFIs with the combination of caspofungin and amphotericin (or liposomal amphotericin)...
  25. ncbi request reprint Antibody therapy in acute myeloid leukemia: current status and future directions
    John M Burke
    Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Lymphoma 2:S12-8. 2002
    ..Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML...
  26. ncbi request reprint A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia
    Mark A Weiss
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 95:581-7. 2002
    ..The authors studied a regimen that contained high-dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease...